Abstract

Background: Myasthenia Gravis and Guillain-Barré syndrome are two of the most common autoimmune diseases affecting the peripheral nervous system in the world. Both of the diseases manifested as progressive muscle weakness, areflexia, and inspiratory muscle weakness which leads to mechanical ventilation support. Therapeutic Plasma Exchange is the first line of treatment according to the American Society for Apheresis (AFSA), which is a relatively safe and often performed procedure In the Intensive Care Unit (ICU), including in Hasan Sadikin Hospital Bandung (RSHS). Purpose: The goal of this study is to obtain the background characteristics of MG and GBS patients and to obtain the outcome of TPE in these patients. Methods: The study was a descriptive study performed on 30 MG and GBS patients who received TPE in the Intensive care unit, RSHS from January 2017 to December 2020. Data for the study was obtained retrospectively from the patient medical record. Results: The result showed that the most common side effect during TPE was electrolyte imbalance. There was no reported morbidity and mortality in MG patients, in contrast to two mortality cases in GBS patients. Length of stay in the intensive care unit was influenced by several factors including age, comorbidities, the severity of MG, and morbidities that occurred during the hospital stay. Conclusion: Outcome of MG and GBS patients with TPE procedure is good in relation with low TPE-unrelated morbidity and mortality.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.